Clinical Trial Update: Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating ezetimibe/simvastatin and MK0524A in mixed hyperlipidemia with multiple risk factors was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Hyperlipidemia

Drugs mentioned

• MK0524A
• ezetimibe/simvastatin (ezetimibe/simvastatin)

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: Cardiovascular Diseases, Hyperlipidemia | Phase 4 | Status: WITHDRAWN